anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject agent containing an essence of a plant of the family Labiatae as an active component and capable of effectively suppressing hydroxy radical harmful to human body. SOLUTION: This agent is composed of an essence of a plant of the family Labiatae (preferably spearmint, peppermint, watermint, Japanese mint, sage or rosemary). The essence is preferably the extract of the plant or the residue left after distilling off the solvent from the extract. The extraction is carried out by adding 1-50 pts. (based on 1 pt. of the plant or its processed product) of a solvent (e.g. methanol, ethanol or methyl acetate) and immersing the plant in the solvent for several days at normal temperature or several hours at a temperature near the boiling point of the solvent. The generation of hydroxy radical is easily suppressed by adding the agent to a composition such as cosmetics or foods.
Participants randomised to the exercise training intervention will complete 24 moderate-intensity exercise training sessions over the subsequent six weeks (four times per week; \~50 min per session). Each week, one exercise training session will be supervised by the research team, whilst three sessions will be unsupervised but monitored objectively using a heart rate monitor.
This study will perform a retrospective analysis to evaluate the effectiveness of a multicomponent educational intervention to improve medication use and management of behavioral and psychological symptoms of dementia, relative to a statewide intervention that has been ongoing. Medication use and symptom severity outcomes will be compared among 29 intervention counties and 10 demographically similar non-intervention counties. The long-term effectiveness of the statewide intervention will also be evaluated. Medicare and Minimum Data set data from 2011 to 2014 will be used to evaluate prescribing and other outcomes in 1) outpatients with dementia, and 2) nursing home residents, based on exposure to interventions among healthcare and nursing home providers. Measurable goals included increasing the appropriateness of antipsychotic prescribing and reducing anticholinergic use. Effect modification will be evaluated by level of participation in the intervention and other prescriber and nursing home facility characteristics.
The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health professional with a nursing background previously certified to coach SSE trainings by the Institute of Square-Stepping Exercise in Mie, Japan (Chief Tomohiro Okura and Overseas Director Professor Ryosuke Shigematsu).
Tribenzor.

Impaired renal function was reported in 2.1% of subjects receiving Tribenzor compared to 0.2% to 1.3% of subjects receiving dual combination therapy of olmesartan medoxomil and amlodipine, olmesartan medoxomil and hydrochlorothiazide or amlodipine and hydrochlorothiazide.

If progressive renal impairment becomes evident consider withholding or discontinuing Tribenzor.

Olmesartan medoxomil.Changes in renal function occur in some individuals treated with olmesartan medoxomil as a consequence of inhibiting the renin-angiotensin-aldosterone system. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria or progressive azotemia and (rarely) with acute renal failure and/or death. Similar effects may occur in patients treated with Tribenzor due to the olmesartan medoxomil component [seeDrug Interactions (7.2) andClinical Pharmacology (12.3)]. 

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar effects would be expected with Tribenzor because of the olmesartan medoxomil component.

Hydrochlorothiazide.Thiazides may precipitate azotemia in patients with renal disease. Cumulative effects of the drug may develop in patients with impaired renal function.
Recurrent DNA break clusters (RDCs) are replication-transcription collision hotspots; many are unique to neural progenitor cells. Through high-resolution replication sequencing and a capture-ligation assay in mouse neural progenitor cells experiencing replication stress, we unravel the replication features dictating RDC location and orientation. Most RDCs occur at the replication forks traversing timing transition regions (TTRs), where sparse replication origins connect unidirectional forks. Leftward-moving forks generate telomere-connected DNA double-strand breaks (DSBs), while rightward-moving forks lead to centromere-connected DSBs. Strand-specific mapping for DNA-bound RNA reveals co-transcriptional dual-strand DNA:RNA hybrids present at a higher density in RDC than in other actively transcribed long genes. In addition, mapping RNA polymerase activity uncovers that head-to-head interactions between replication and transcription machinery result in 60% DSB contribution to the head-on compared to 40% for co-directional. Taken together we reveal TTR as a fragile class and show how the linear interaction between transcription and replication impacts genome stability.
A system for hygienic input of data into a medical information system is provided. In one embodiment of the system, a computer terminal, a mobile wireless input tray, a mobile wireless interactive visual display system, and a wireless headset are used. During a medical procedure, the mobile input tray, the mobile display system, and the wireless headset may be positioned in an operating room near a surgeon or other medical practitioner. The mobile input tray, the mobile display system, and the wireless headset may be used to access patient medical information through the computer terminal. The mobile input tray, the mobile display system, and the wireless headset communicate amongst and between each other through wireless communication links. The mobile input tray, the mobile display system, and the wireless headset communicate with the computer terminal through wireless communication links.
The experimental group will receive a digital letter with information on the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-THP-APN09 PET/CT scans.
FIELD: medicine, biotechnology. SUBSTANCE: method of preparing shark cartilage extracts involves preparing a mixture of whole cartilage with an aqueous solution at neutral pH value, preferably with pure water. This mixture is centrifuged and sediment and supernatant after centrifugation are remained for the further treatment. Sediment after centrifugation is lyophilized and tested for the presence antitumor and antiangiogenic activities in vivo and in vitro in the presence or absence of supernatant. Supernatant was found to show antiangiogenic and tumor-regressing activities in vivo. After fractionation of supernatant some of its active components are characterized and these components show direct inhibiting effect on tumor cell strains. Methods provide preparing shark cartilage extracts enhancing the effectiveness of treatment of patients with angiogenesis-dependent diseases. EFFECT: improved method of preparing, enhanced effectiveness of treatment. 24 cl, 14 dwg
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) asscociated hepatocellular carcinoma (HCC) is becoming a growing concern in global healthcare. The early-life gut microbiota plays a crucial role in maintaining healthy. However, the impact of early-life gut microbiota dysbiosis on the advancement of MASLD-HCC remains inadequately understood.
METHODS: In the present study, we investigated the role of early-life gut microbiota in the development of MASLD-HCC in streptozotocin and high-fat diet (STZ-HFD) induced mouse model. We recorded the body weight and lifespan, and dynamically monitored the level of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), total cholesterol (T-CHO) and blood glucose in the serum monthly. In addition, we examined various immune cells present in the liver, such as T cells, B cells, NK cells, NKT cells, αβT cells, γδT cells, macrophage and MDSC cells by flow cytometry and conducted liquid chromatography mass spectrometry (LC-MS) based analysis on liver tissue from control and early-life antibiotic exposure mice (early-Abx) MASLD-HCC mice.
RESULTS: We found that early-Abx mice suffered from more severe tumor burden and further confirmed that hepatocytes and immune cells were all disturbed. Importantly, early-life antibiotic exposure alters the liver metabolic profiling especially glycerophospholipids and lipid accumulation. Furthermore, mice exposed to antibiotics in early-life showed disturbances in glucose metabolism and developed insulin resistance.
CONCLUSIONS: Collectively, our findings revealed that early-life antibiotic exposure accelerated the progression of MASLD-HCC by impairing the hepatocytes, immune homeostasis and metabolites persistently, highlighting the importance of the early-life microbiota in the development of MASLD-HCC.
Intestinal fibrosis is a common complication in patients with inflammatory bowel disease [IBD], in particular Crohn's disease [CD]. Unfortunately, at present intestinal fibrosis is not yet preventable, and cannot be treated by interventions other than surgical removal. Intestinal fibrosis is characterized by excessive accumulation of extracellular matrix [ECM], which is caused by activated fibroblasts and smooth muscle cells. Accumulation of ECM results from an imbalanced production and degradation of ECM. ECM degradation is mainly performed by matrix metalloproteinases [MMPs], enzymes that are counteracted by tissue inhibitors of MMPs [TIMPs]. In IBD patients, MMP activity [together with other protease activities] is increased. At the same time, CD patients have a generally lower MMP activity compared to ulcerative colitis patients, who usually do not develop intestinal strictures or fibrosis. The exact regulation and role[s] of these MMPs in fibrosis are far from understood. Here, we review the current literature about ECM remodelling by MMPs in intestinal fibrosis and their potential role as biomarkers for disease progression or druggable targets.
In addition to regular care: Up to 8 appointments in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. In case that a patients fails to meet target values, preventive measures will be modified directly or via recommendation to GPs / family doctors. Patients are also offered assistance in finding appropriate physical activities or smoking cessation programs.
OBJECTIVES: Ischemic stroke is a common and debilitating disease that can cause permanent neurological damage. Gucy1a3, which encodes the α1 subunit of soluble guanylyl cyclase, has been reported to be associated with functional recovery after ischemic stroke. However, the mechanism is still not well understood. In the present study, we investigated the effects of Gucy1a3 on (i) post-stroke recovery; (ii) vascular endothelial growth factor A (VEGFA) and hypoxia inducible factor 1 alpha (HIF-1α) expression; and (iii) angiogenesis after ischemic stroke.
MATERIALS AND METHODS: Wild-type and Gucy1a3 knockout C57BL/6J male mice were respectively used to establish the models of permanent middle cerebral artery occlusion (pMCAO). Neurological deficit scores were evaluated at 24 h and 96 h after pMCAO. Cerebral infarct volume was measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining. For determining microvessel density, immunohistochemical analysis was performed with CD31. The expression of VEGFA and HIF-1α was detected by western blotting.
RESULTS: Our results suggest that loss of Gucy1a3 increased the infarct volume and aggravated neurological deficits after pMCAO. In addition, the Gucy1a3 knockout brains exhibited significantly lower microvessel densities and VEGFA and HIF-1α expression levels than the wild-type brains at 96 h post-pMCAO.
CONCLUSIONS: Our study indicates that GUCY1A3 might be involved in angiogenesis after ischemic stroke. Further investigation of GUCY1A3 will provide a new therapeutic target for stroke.
1. A cosmetic product for delivery of skin with actives which includes: (A) a strip comprising: (i) a flexible substrate sheet; and (ii) a composition containing a polymer, selected from the group consisting of anionic, cationic, nonionic, amphoteric, zwitterionic (amphionic) polymers and polymer mixtures thereof deposited onto the substrate sheet, wherein the amount of polymer ranges from 75 to 99% by weight of composition deposited onto the substrate sheet, the composition further comprising an active ingredients, selected from the group consisting of vitamins, herbal extracts, alpha- and beta- oxycarboxylic acids, ceramides, anti-inflammatories, antimicrobials, vasoconstrictors, zinc salts and mixtures thereof; the composition increasing in tackiness upon being wetted just prior to use thereby enhancing the composition adhesivity to skin; and (B) a pouch sealably enclosing the strip. 2. The product according to Claim 1 wherein the vitamins selected from the group consisting of Vitamin A, Vitamin B, Vitamin C, Vitamin E and combinations thereof. 3. The product according to Claim 2 wherein the Vitamin C is selected from the group consisting of ascorbic acid, magnesium ascorbyl phosphate, ascorbyl palmitate, L-ascorbyl stearate, dehydroascorbic acid, vitazyme C and combinations thereof. 4. The product according to any of preceding Claims, wherein the amount of active ingredients ranges from 1 to 25% by weight. 5. The product according to any of preceding Claims wherein the sheet is rayon. 6. The product according to any of preceding Claims, wherein the deposited composition and substrate sheet are present in a weight ratio ranging from 0.1:1 to 1,000:1. 7. The product according to any of preceding Claims, wherein the polymer is a vinylpyrrolidone. 8. The product according to any of preceding Claims, wherein the polymer is a polymethylvinyl ether/maleic anhydride copolymer. 9. The use of a product according to any of preceding Claims for delivery of skin with moisture-sensitive actives, selected from the group consisting of vitamins, herbal extracts, alpha- and beta- oxycarboxylic acids, ceramides, anti-inflammatories, antimicrobials, vasoconstrictors, zinc salts and mixtures thereof.
FIELD: medicine, pharmacy technology. SUBSTANCE: invention proposes a new antiasthmatic drug as tablets that has the following components, wt.-%: theophylline monohydrate 14.2-16.2; caffeine monohydrate 7.2-9.5; paracetamol 31.7-35.0; phenobarbital 2.8-3.8; ephedrine hydrochloride 2.8-3.8; deadly night-shade (belladonna) extract 0.4-0.6; cytisine 0.016-0.018; polyvinylpyrrolidone 1.8-2.2; calcium stearate 0.1-1.0; stearic acid 0.1-1.0, and potato starch - the rest. Method of preparing tablets showing antiasthmatic effect involves preparing mass for tabletting by successive mixing half doses of paracetamol and potato starch with ephedrine hydrochloride, phenobarbital, caffeine monohydrate, theophylline monohydrate and then - with the remained half doses of paracetamol and potato starch. Obtained mixture is wetted with polyvinylpyrrolidone solution containing dissolved belladonna extract and cytisine and then mixture is wetted with a mixture of polyvinylpyrrolidone solution with starch filling solution. Then wet granulation, drying and dry granulation are carried out and then mass is powdered with potato starch, calcium stearate, stearic acid and tabletted. Tablets of new agent have the improved disruption, solubility and bioavailability of active components. EFFECT: improved method of preparing. 3 cl, 2 ex
PURPOSE:To provide the titled remedying liquid, by mixing powdery boric acid with hot water, and adding soap to the mixture. CONSTITUTION:Powdery boric acid (4%) is mixed with hot water (5%) of 80 deg.C to obtain a soft slurry product having dark white color and short texture. The product has weak sterilizing and strong deodorizing properties. The product is mixed with stock liquid of a halogen-containing neutral chemical detergent (prepared from petroleum, liquefied coal, or alkylbenzene) to obtain the first compound. The first compound is made to react with fluorine gas supplied from an iron bomb under a pressure of 10-40atm at a concentration of 200ppm through a rubber tube to obtain the second compound having strong sterilizing property. The second compound is added to the first compound in 5-6 divided portions, and stirred gently to effect the reaction. The liquid agent for the complete cure of athlete's foot and having inorganic, foamy and transparent nature can be obtained by this process. The agent is effective also to various pain of lymphoglandula, achillodynia, rheumatalgia, neuralgia, etc.
The present invention relates to a kind of liver and gallbladder row's stone drinks, are made of following weight parts raw material: 10-20 parts of Artemisia capillaris, 5-15 parts of rheum officinale, 5-10 parts of sea salt, 50-150 parts of olive oil, 50-150 parts of lemon juice；Artemisia capillaris, rheum officinale, sea salt are No. 1 medicine；Olive oil is No. 2 medicines；Lemon juice is No. 3 medicines；No. 1 every agent dose of medicine is Artemisia capillaris 10-20g, rheum officinale 5-15g, sea salt 5-10g；No. 2 every agent doses of medicine are olive oil 50-150ml；No. 3 every agent doses of medicine are lemon juice 50-150 ml, the liver and gallbladder arrange the treatment of stone kitchenware body are as follows: first five day of patient is allowed to take one No. 1 medicine daily, 6th day under meal situation, take the mixed liquor for taking one No. 2 medicines and No. 3 medicines after one No. 1 medicine for six hours, 7th day morning drank more water after taking one No. 1 medicine, was sequentially completed three course of therapy.At low cost, devoid of risk of the invention has the function of that liver and gallbladder recovery, reduction are fallen ill repeatedly.
The invention is purposely for Orthosiphon stamineus extracts administration in dermal skin layer. Human skin consists of epidermis, dermis and hypodermis. Epidermis or also known as stratum corneum is located at the outermost layer of the skin. This stratum corneum acts as a barrier; hence most topical products cannot penetrate it. The impermeability of stratum corneum is due to the intercellular space filled with a lipid-rich matrix arranged in a laminar fashion which consequently leads to robust and waterproofing barrier Therefore, suitable carrier is important to preserve physicochemical characteristics of Orthosiphon stamineus extracts and the carrier must be small enough (nanosize) to penetrate through skin. In drug delivery, the usage of nanoparticles is where the drug is dissolved, entrapped, encapsulated or attached to a nanoparticle matrix. Nanoparticles are microscopic particles whose size is measured in nanometer in range of 10 to 1000 nm. The present invention relates to a nanostructured lipid carrier comprising Orthosiphon stamineus extracts encapsulated in lipid matrix, said lipid matrix consisting of triglyceride, glyceryl monostearate, surfactant and water. (Figure 2)
PURPOSE:To obtain the subject new peptide conjugate capable of inhibiting infiltration of a cancer cell during a process of cancer cell metastasis and useful as a cancer metastasis inhibitor by chemically bonding a peptide having a specified amino acid sequence to a biopolymer such as a protein. CONSTITUTION:A peptide is synthesized using an automatic peptide synthesizer by the Merribield solid phase synthesis method and the resultant product is subsequently subjected to high-performance chromatography to elute the peptide by the linear concentration gradient method. The peptide having an amino acid sequence represented by formulae I-VIII (Glx is Glu or Gln; Asx is Asn or Asp) and showing a cancer metastasis inhibitory effect can be obtained thereby. The above-obtained peptide and a biopolymer (e.g. mouse serum albumin) such as an organism-derived protein are then dissolved in distilled water and pH of the resultant solution is adjusted to 8.5 by a sodium hydroxide solution. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide solution is added thereto and reacted at 37 deg.C for 2hr, thus giving the objective peptide conjugate in which the peptide is chemically bonded to the biopolymer.
The invention relates to a tangerine powder microcapsule anti-oxidation face mask liner, a preparation method and application of the same. The face mask liner is prepared through post-arrangement and post-processing of a tangerine powder microcapsule finishing agent on a non-woven fabric; and the non-woven fabric face mask liner is placed between the inner layer and the outer layer of the face mask as an interlayer material. The involved tangerine powder anti-oxidation microcapsule finishing agent is prepared by a microcapsule technology. Flavonoid compounds in tangerine powder have obvious effects of oxidation resistance and free radical scavenging, and have assistant effects in aspects such as inflammation diminishment, cancer prevention, anticoagulation, thrombus prevention and prevention and treatment of heart and cerebral vessel diseases. Hence, the face mask liner provided by the invention is characterized in that the liner is efficient in oxidation resistance, can scavenge free radicals in air, is safe and pollution-free, has a good scent, etc. The liner is a green, environment-friendly, anti-oxidation and multi-functional textile product.